NASDAQ:TBPH Theravance Biopharma Q2 2026 Earnings Report $17.03 0.00 (0.00%) As of 10/1/2026 ProfileEarnings HistoryForecast Theravance Biopharma EPS ResultsActual EPS-$0.11Consensus EPS $0.07Beat/MissMissed by -$0.18One Year Ago EPSN/ATheravance Biopharma Revenue ResultsActual Revenue$20.73 millionExpected Revenue$22.49 millionBeat/MissMissed by -$1.76 millionYoY Revenue GrowthN/ATheravance Biopharma Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time8:30AM ETUpcoming EarningsTheravance Biopharma's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Theravance Biopharma Earnings HeadlinesHead to Head Contrast: Lifecore Biomedical (NASDAQ:LFCR) & Theravance Biopharma (NASDAQ:TBPH)October 1 at 2:15 AM | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Stock Rating Reaffirmed as "Neutral" by BTIG ResearchSeptember 26, 2026 | americanbankingnews.comHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.October 2 at 1:00 AM | Chaikin Analytics (Ad)Theravance Biopharma (NASDAQ:TBPH) vs. Fortress Biotech (NASDAQ:FBIO) Head-To-Head ComparisonSeptember 25, 2026 | americanbankingnews.comTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness IndexSeptember 24, 2026 | marketscreener.comMZymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.September 24, 2026 | de.marketscreener.comDSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and other serious conditions. The company’s work centers on therapies designed to address unmet needs in areas such as chronic obstructive pulmonary disease (COPD) and related respiratory disorders. Its principal commercial product is YUPELRI (revefenacin), an inhaled long-acting muscarinic antagonist used as a once-daily maintenance treatment for COPD. YUPELRI is commercialized in collaboration with Viatris. Theravance also receives royalties associated with certain respiratory products developed through its collaboration with GlaxoSmithKline, including the products marketed as Trelegy Ellipta. Theravance Biopharma was established in 2013 following the separation of its biopharmaceutical operations from Theravance, Inc. The company is headquartered in Dublin, Ireland, and relies on commercial and development partners to support the availability of its medicines in the United States and selected international markets. Rick E. Winningham has served as the company’s chief executive officer since its formation.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
